Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

ket Opportunity in HCV Infection

Chronic HCV infection is a serious public health concern affecting approximately 3.2 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which can lead to fibrosis and cirrhosis, and may ultimately lead to liver failure and/or liver cancer if not successfully treated. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-sta
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... and MOUNTAIN VIEW, Calif. ... a recognized leader in translational preclinical research, today unveiled ... www.surpassinc.com ), signaling the transformation of Surpass, corporate culture ... partner for our customers. This press release comes on ... integral hires were added to the Silicon Valley Team: ...
(Date:7/23/2014)... 2014 NOT FOR RELEASE, PUBLICATION ... IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO ... OF SUCH JURISDICTION. AbbVie (NYSE: ABBV ... July 25, 2014, before the market opens. AbbVie ... at 8 a.m. Central time (9 a.m. Eastern). It will ...
(Date:7/23/2014)... , July 23, 2014  RT Oncology Services Corporation ... to join its board of directors. Mr. Mundie is ... where he works on strategic projects within the company ... Microsoft,s chief research and strategy officer. ... of RainTree, said, "Craig is a visionary technology executive. ...
Breaking Medicine Technology:SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3
... DALLAS, March 10 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... conference call for March 13, 2008 at 10:00 a.m. ... its clinical trial programs as,well as its business opportunities., ... dialing (877),407-8293; callers outside the U.S. may participate by ...
... Reported at AAOS Annual Meeting Support Longterm ... ... GENZ ), today announced findings from a large, multicenter,observational study that ... had pain and,functional impairment from defects in the articular cartilage of ...
Cached Medicine Technology:Access Pharmaceuticals to Conduct Conference Call to Update Financial Community 2Genzyme Announces Presentation of New Positive Data on Carticel(R) 2Genzyme Announces Presentation of New Positive Data on Carticel(R) 3Genzyme Announces Presentation of New Positive Data on Carticel(R) 4Genzyme Announces Presentation of New Positive Data on Carticel(R) 5Genzyme Announces Presentation of New Positive Data on Carticel(R) 6
(Date:7/23/2014)... If past experience is anything to go by, ... get a lot more recognition for their contributions to ... allowing NPs to provide primary care offer nurses more ... relationships with physicians and administrators, compared with colleagues in ... School of Nursing, published in Health Care Management ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, ... children and teens look in the mirror and tell ... Wednesday. "Being overweight or obese is associated with ... cholesterol and diabetes," said lead researcher Neda Sarafrazi, a ... and Prevention,s National Center for Health Statistics. "Children ...
(Date:7/23/2014)... 2014 The next episode of “Extreme ... Wis. who was physically fit through childhood and adolescence. ... made the heart-wrenching decision to give her son up ... past 18 years, and she punished herself by overeating, ... a unique, non-competitive approach to weight loss transformations, “Extreme ...
(Date:7/23/2014)... Home Care Assistance Calgary , North ... proud to announce the next installment in its renowned ... range of health and wellness-related fields. The upcoming webinar ... Nancy Kriseman, and will cover the most common causes ... becoming more self-aware. In particular, Nancy will discuss mindfulness ...
(Date:7/23/2014)... -- Painful or itchy skin lesions could be a ... sometimes have multiple lesions that are suspicious looking, and ... concerns for non-melanoma skin cancers," study author Dr. Gil ... Medicine, said in a Temple University Health System news ... 268 patients who were confirmed to have skin cancer ...
Breaking Medicine News(10 mins):Health News:New York law offers nurses more recognition, responsibility 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2
... Studies Presented at EuroSpine are Among Several Demonstrating ... Minimally Invasive Procedure, AUSTIN, Texas, Oct. 2 ... be presented this week at EuroSpine in Brussels,found ... with contained,disc herniation. PDD is a minimally invasive ...
... - Flatulence isn,t much fun,for the person having it - or those nearby. The October ... -- Slow down your eating: A little bit of ... you swallow. To reduce the amount of air, eat and ... -- Avoid airy drinks and foods: Air also gets into the gut ...
... The U.S. hospital marketplace,has become a battleground ... on hospital formularies. Among the challenges: It,s never ... and the list of formulary,decision-makers continues to grow. ... way into formularies via,specialized training classes that focus ...
... Imaginative learning, play may help, study suggests , TUESDAY, Oct. ... with toy blocks -- may help boost the language development ... The pilot study of 175 children ages 1.5 to 2.5 ... the study, the children were divided into two groups. One ...
... S.C., Oct. 2 The Medical University of,South ... the,Spaulding- Paolozzi Foundation to create the Countess Alicia ... and,Research. Hollings Cancer Center will provide matching funds ... million Chair will allow Hollings Cancer Center to ...
... Organization,s Focus ... on Breast Cancer Disparities, DALLAS, Oct. ... in the breast cancer movement, has appointed Amelie G. Ramirez,DrPH, ... http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ) Ramirez joins a group of ...
Cached Medicine News:Health News:New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation 2Health News:New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation 3Health News:New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation 4Health News:Fighting the Gassy Effects of Good Eating, From the Harvard Health Letter 2Health News:Equipping your Sales Force to Influence Hospital Formulary Decision-Makers 2Health News:Toy Blocks Might Boost Toddlers' Language Skills 2Health News:Hollings Cancer Center Creates $1 Million Endowed Chair for Breast Cancer Research and Treatment with Gift from the Spaulding-Paolozzi Foundation 2Health News:Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board 2Health News:Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board 3
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
... mobile surgical stretcher. M-701 Stretcher has ... in. to 32 in., measured with ... specify a high range, 28 in. ... in. pad can be supplied optionally. ...
... is a staining solution for cataract ... for performing a safe phaco-emulsification procedure. ... capsule may result in an incomplete ... of radial capsule tears and associated ...
Medicine Products: